TRAVERE THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
TRAVERE THERAPEUTICS, INC. (TVTX) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value of $275.55 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue · last filed 2026-08-04
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $275.55M.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $77.15M.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $150.80M.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $46.86M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value as first filed |
|---|---|---|
| 2026-06-30 | $275.55M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $77.15M 10-Q · filed 2026-05-04 | |
| 2025-12-31 | $150.80M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $46.86M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $9.48M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $17.86M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $16.41M 10-Q · filed 2025-10-30 | $0.00 10-Q · filed 2025-05-01 |
| 2014-06-30 | $7.30M 10-Q · filed 2014-08-14 | |
| 2013-12-31 | $172.00K 10-Q · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |